Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides Subtype

Cobomarsen (SOLAR Clinical Trial)    Actively Recruiting

➤ An international Phase 2 clinical trial to test a new investigational drug called cobomarsen for the potential treatment of cutaneous T-cell lymphoma (CTCL), mycosis fungoides subtype. This study will be open in the United States, Canada, Europe and Australia.

Cobomarsen is designed to inhibit a molecule called miR-155 that is found at high levels in certain types of cancer, including mycosis fungoides, and which may be important for the cancer cells to survive and grow. Participants in this study will be randomly assigned to receive either cobomarsen or vorinostat, a drug that has been approved for the treatment of mycosis fungoides in the United States, Canada and Australia. The potential benefits and side effects of cobomarsen in patients with mycosis fungoides will be compared with those of vorinostat.

More information on this study can be found here.

Cobomarsen Phase 1 clinical trial data presented at the 2018 American Society of Hematology annual meeting can be found here.

Patient Resources: